Isomorphic Labs, a company within the Alphabet structure, has closed a Series C funding round in the amount of $5 billion. The round was led by the funds Greenoaks and Sequoia Capital, and the valuation of the developer of AI systems for drug discovery reached approximately $50 billion.

The raised capital will be directed toward two key areas: further development of its own IsoDDE platform and advancement of a portfolio of drugs against oncological and immune diseases. At present, all of the company's developments are at the preclinical stage — that is, there is still a significant path to go before the stage of human trials.

What stands behind the $50 billion valuation

Such a high capitalization in the absence of commercial products is a direct reflection of market expectations regarding the potential of AI in pharmaceuticals. The IsoDDE platform is positioned as a tool capable of radically reducing the timelines and cost of preclinical research, which traditionally take years and require enormous budgets. The participation of institutional investors such as Greenoaks and Sequoia Capital signals the readiness of venture capital to finance long-term and high-risk AI projects in the healthcare sector.

For Alphabet, this is a strategic bet on diversification beyond the advertising and cloud business. Pharmaceuticals, with its high barriers to entry and enormous margin opportunities upon successful market launch of a drug, represents an attractive long-term goal. However, the path from the preclinical stage to regulatory approval remains unpredictable in terms of timelines and is fraught with the risk of clinical trial failure.

Cryptalist Analysis: The round demonstrates that capital continues to concentrate around AI platforms with breakthrough potential, even in the absence of revenue and commercial products. The $50 billion valuation prices in virtually flawless execution of the clinical program, which creates a significant risk of overvaluation in the event of any delays or trial failures. For the AI pharmaceuticals market, this is simultaneously a confirmation of the sector's maturity and a signal of the formation of a new bubble of expectations.